Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
View on Grants.gov ↗ Sign in to save
- Type
- Grant forecast
- Notice type
- G
- Agency
- Food and Drug Administration
- Sub-agency
- HHS-FDA
- Solicitation #
- FOR-FD-25-001
- Posted
- Aug 14, 2024
- CFDA / Assistance listing
- 93.103
- Award floor
- $650,000
- Award ceiling
- $900,000
- Contact
- Terrin Brown Grantor · terrin.brown@fda.hhs.gov · 2404027610
- Source
- Grants.gov
Description
The purpose is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare neurodegenerative diseases for children and adults. Through the support of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare neurodegenerative diseases and exert a broad and positive impact on rare disease drug development.